🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The figure we all have to learn by heart: The updated Lancet Commission on potentially modifiable risk factors for dementia. #AAIC24

Time for an update! Ismael Calandri Gill Livingston Regina Paradela Lucía Crivelli Ricardo F. Allegri Claudia Suemoto MD PhD MSc

The BeyeOMARKER study design paper is out! In BeyeOMARKER we will screen 700 individuals with plasma p-tau217 at an eye clinic, and further characterize 150 of them with Amyloid & Tau PET, MRI, retinal imaging and cognitive & cortical vision assessment. Thanks to the great team

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies Very elegant work from BioFINDER, led by @alexa_pichetb, Jake Vogel & Oskar Hansson. Link at Nature Neuroscience > nature.com/articles/s4159…

Very proud of Anna Svenningson who defended her PhD thesis today very well. Also many thanks to opponent Prof. Geir Saelback for creating a great atmosphere leading to a high-level scientific discussion about resilience in Alzheimer’s disease. W/Oskar Hansson Sebastian Palmqvist

Lewy body pathology exacerbates brain hypo-metabolism and cognitive decline in Alzheimer’s disease Great work led by Lyduine Collij. Using ADNI data, she showed that the presence of LB pathology (CSF SAA) exacerbates global cognitive decline in symptomatic AD and is associated with

I attended the FTD-ALS workshop (isFTD pre-conference in Amsterdam) this morning, learned a lot about TDP-43!

isFTD2024 in Amsterdam has started! A great musical intro, official opening by local organizer Yolande Pijnenburg (Alzheimercentrum Amsterdam (inactief)), a touching speech by Emma Heming Willis (FTD advocate and partner of Bruce Willis) and an opening plenary by Elisabet Englund (Lund University)

Association of in vivo retention of Flortaucipir PET with tau neuropathology in corresponding brain regions Check out our most recent publication, led by Tove Freiburghaus & Daria Pawlik at Acta Neuropathologica. Main findings: 1⃣ Flortaucipir PET signal primarily reflects tau

On the train back to Amsterdam after a wonderful first EU-MIND Congress, I think is here to stay! It was a pleasure to give a talk on “AT(N) imaging in atypical variants of Alzheimer’s disease”.

REAL AD - Validation of a realistic screening approach for early Alzheimer's disease This large-scale study led by Michael Schöll will learn us a lot about population-based screening with plasma biomarkers of Alzheimer's disease pathophysiology. Link to the design paper

Pointing at the culprit.

Pleased to present our recent publication Alzheimer’s Research & Therapy on "Biological mechanisms of resilience to tau pathology in Alzheimer’s disease", led by Anna Svenningson and Diana Bocancea. Link to paper: alzres.biomedcentral.com/articles/10.11… w/Erik Stomrud, Niklas Mattsson-Carlgren, Sebastian Palmqvist,

Pleased to present the design paper of a Dutch multicenter study in which we aim to assess the clinical value of Tau PET, led by Marie R. Vermeiren (Alzheimercentrum Amsterdam (inactief)). "The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP- TAU study" Link to

📢Job alert! Join the BioFINDER team as a Grant Manager👇🏽

IWG 2024 vs AA 2024 criteria for Alzheimer disease A comparison between the recently proposed Alzheimer Association criteria vs the updated IWG criteria for AD. Differences are in the Table below: mainly comprising differing views on AD as a "biological" vs "clinical-biological"

FYI.

Survey among experts on the future role of tau-PET in clinical practice and trials Check out our latest work led by Marie R. Vermeiren & Ismael Calandri, describing the results of a survey among 268 dementia experts on the future role of Tau PET in the clinic and trials. Many

🚨NEW PREPRINT: An atypical phenotype is a risk factor for higher mortality in Alzheimer’s disease Ilse Bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and

So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠 🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey: alz.surveymonkey.com/r/923BTQK